Open AccessSustained Release of Bone Morphogenetic Protein 2 via Coacervate Improves the Osteogenic Potential of Muscle‐Derived Stem Cells
Author(s) -
Li Hongshuai,
Johnson Noah Ray,
Usas Arvydas,
Lu Aiping,
Poddar Minakshi,
Wang Yadong,
Huard Johnny
Publication year - 2013
Publication title -
stem cells translational medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.781
H-Index - 71
eISSN - 2157-6580
pISSN - 2157-6564
DOI - 10.5966/sctm.2013-0027
Subject(s) - coacervate , bone morphogenetic protein , microbiology and biotechnology , bone morphogenetic protein 2 , stem cell , chemistry , bone morphogenetic protein 7 , biomedical engineering , biophysics , biology , biochemistry , medicine , in vitro , gene
A unique growth factor delivery platform comprised of native heparin and a synthetic polycation, poly(ethylene argininylaspartate diglyceride) (PEAD), was used to bind, protect, and sustain the release of bone morphogenetic protein‐2 (BMP2) in a temporally and spatially controlled manner. Prolonged exposure to BMP2 released by the PEAD:heparin delivery system promoted the differentiation of muscle‐derived stem cells (MDSCs) to an osteogenic lineage in vitro and induced the formation of viable bone at an ectopic site in vivo. This new strategy represents an alternative approach for bone repair mediated by MDSCs while bypassing the need for gene therapy.